PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-20.00%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-57.72%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-544.67%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-544.67%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
487.94%
Net income growth above 1.5x XRF.AX's 13.78%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
234.62%
EPS growth above 1.5x XRF.AX's 12.54%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
280.00%
Diluted EPS growth above 1.5x XRF.AX's 12.54%. David Dodd would see if there's a robust moat protecting these shareholder gains.
74.90%
Share count expansion well above XRF.AX's 1.21%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
58.90%
Diluted share count expanding well above XRF.AX's 1.24%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-3736.36%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
31.79%
10Y revenue/share CAGR under 50% of XRF.AX's 151.40%. Michael Burry would suspect a lasting competitive disadvantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
10Y OCF/share CAGR at 75-90% of XRF.AX's 132.15%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
216.80%
Similar net income/share CAGR to XRF.AX's 198.79%. Walter Schloss would see parallel tailwinds or expansions for both firms.
No Data
No Data available this quarter, please select a different quarter.
137.30%
3Y net income/share CAGR above 1.5x XRF.AX's 72.97%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Our R&D shrinks while XRF.AX invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-77.11%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.